½ÃÀ庸°í¼­
»óǰÄÚµå
1684488

ÀÎÇ÷翣ÀÚ Áø´Ü ½ÃÀå : ¼¼°è »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2025-2032³â)

Influenza Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Persistence Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 237 Pages | ¹è¼Û¾È³» : 2-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÁÖ¿ä ÀλçÀÌÆ®

  • ÀÎÇ÷翣ÀÚ Áø´Ü ½ÃÀå ±Ô¸ð : 18¾ï 330¸¸ ´Þ·¯(2025³â)
  • ¿¹»ó ½ÃÀå ±Ô¸ð : 27¾ï 1,150¸¸ ´Þ·¯(2032³â)
  • ¼¼°è ½ÃÀå ¼ºÀå·ü : 6.00%(2025-2032³â CAGR)

ÀÎÇ÷翣ÀÚ Áø´Ü ½ÃÀå - º¸°í¼­ ¹üÀ§

ÀÎÇ÷翣ÀÚ Áø´Ü ½ÃÀåÀº AÇü, BÇü, CÇü ÀÎÇ÷翣ÀÚ¸¦ Æ÷ÇÔÇÑ ÀÎÇ÷翣ÀÚ ¹ÙÀÌ·¯½ºÀÇ °ËÃâ ¹× ½Äº°¿¡ »ç¿ëµÇ´Â Áø´Ü µµ±¸ÀÇ °³¹ß ¹× º¸±Þ¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀº °èÀý¼º ÀÎÇ÷翣ÀÚ ¹× À¯Ç༺ ÀÎÇ÷翣ÀÚ À¯ÇàÀÇ Áõ°¡, ½Å¼ÓÇϰí Á¤È®ÇÑ Áø´Ü °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ºÐÀÚ °Ë»ç ¹× Ç÷ûÇÐ °Ë»çÀÇ ±â¼úÀû Áøº¸¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Áúº´ ¹ß»ýÀ» ¾ïÁ¦Çϱâ À§ÇÑ Á¶±â ¹× Á¤È®ÇÑ °ËÃâ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ÀÇ·á ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡´Â ½ÃÀå È®´ë¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ

¼¼°è ÀÎÇ÷翣ÀÚ Áø´Ü ½ÃÀåÀº Àü ¼¼°è ÀÎÇ÷翣ÀÚ °¨¿° ºÎ´ã Áõ°¡, Áúº´ Á¶±â ¹ß°ß¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, Áø´Ü ±â¼ú ¹ßÀü µî ¿©·¯ ¿äÀÎÀ¸·Î ÀÎÇØ Å« ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. Á¤ºÎ¿Í ÀÇ·á ±â°üÀº ÀÎÇ÷翣ÀÚ °¨½Ã¿Í ´ëºñ¿¡ ÁßÁ¡À» µÎ°í ÀÖÀ¸¸ç, ÀÌ´Â ÀÎÇ÷翣ÀÚ Áø´Ü °Ë»çÀÇ Ã¤ÅÃÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇöÀå °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä¿Í ºÐÀÚÁø´Ü ¹æ¹ýÀÇ È®´ë°¡ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¾ïÁ¦¿äÀÎ

ºÐÀÚÁø´ÜÀº Å« ¼ºÀåÀÌ ¿¹»óµÇ´Â ¹Ý¸é, ³ôÀº ºÐÀÚÁø´Ü ºñ¿ë°ú ÀϺΠÁö¿ª¿¡¼­´Â ÷´Ü ÀÇ·á½Ã¼³¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Á¦ÇÑÀûÀ̶ó´Â ¹®Á¦Á¡¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ½Å¼ÓÁø´Ü °Ë»ç(RIDT)ÀÇ Á¤È®¼ºÀº À§À½¼º °á°ú°¡ Àû½Ã Ä¡·á¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö Àֱ⠶§¹®¿¡ ¿©ÀüÈ÷ ¿ì·ÁÀÇ ´ë»óÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±ÔÁ¦ À庮°ú Áø´Ü ŰƮÀÇ ±î´Ù·Î¿î ½ÂÀÎ ÀýÂ÷µµ ½ÃÀå È®´ë¸¦ Áö¿¬½Ãų ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ±âȸ

ÀÎÇ÷翣ÀÚ Áø´Ü ½ÃÀå¿¡´Â Çõ½ÅÀûÀÎ °í°¨µµ °Ë»ç ¼Ö·ç¼Ç °³¹ß, Áø´Ü Ç÷§Æû¿¡ AI ÅëÇÕ µî Å« ¼ºÀå ±âȸ°¡ ÀÖ½À´Ï´Ù. ½ÅÈï ½ÃÀå ÁøÃâ°ú ÇöÀå °Ë»ç ¼Ö·ç¼Ç¿¡ ´ëÇÑ ÅõÀÚ´Â ½ÃÀå ħÅõ¸¦ ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Áø´Ü Á¦Á¶¾÷ü¿Í ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¿ÍÀÇ Àü·«Àû Á¦ÈÞ¸¦ ÅëÇØ Á¦Ç°ÀÇ Á¢±Ù¼º°ú °¡¿ë¼ºÀ» Çâ»ó½ÃÄÑ ½ÃÀå ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ãų ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ¼¼°è ÀÎÇ÷翣ÀÚ Áø´Ü ½ÃÀåÀ» Á¶»çÇÏ¿© ¼ºÀå ÃËÁø¿äÀÎ, µ¿Çâ, ±âȸ, °úÁ¦ µî ½ÃÀå ¿ªÇп¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå °³¿ä

  • ½ÃÀå ¹üÀ§/ºÐ·ù
  • ½ÃÀå Á¤ÀÇ/¹üÀ§/Á¦ÇÑ
  • Æ÷ÇÔ°ú Á¦¿Ü

Á¦3Àå ÁÖ¿ä ½ÃÀå µ¿Çâ

  • ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä µ¿Çâ
  • Á¦Ç°ÀÇ Çõ½Å/°³¹ß µ¿Çâ

Á¦4Àå Áß¿äÇÑ ¼º°ø¿äÀÎ

  • Á¦Ç° ä¿ë/ÀÌ¿ë ºÐ¼®
  • Á¦Ç° USP/Ư¡
  • Àü·«°ú ÇÁ·Î¸ð¼Ç Àü·«
  • ÁÖ¿ä ±ÔÁ¦
  • Áúº´ ¿ªÇÐ
  • PESTLE ºÐ¼®
  • Porters ºÐ¼®

Á¦5Àå ½ÃÀå ¹è°æ

  • °Å½Ã°æÁ¦ ¿äÀÎ
  • ¿¹Ãø¿äÀÎ - °ü·Ã¼º°ú ¿µÇâ
  • ¿ªÇÐ

Á¦6Àå COVID-19 À§±â ºÐ¼®

  • COVID-19¿Í ¿µÇ⠺м®
    • °Ë»çº°
    • ÀÎÇ÷翣ÀÚ À¯Çüº°
    • ÃÖÁ¾»ç¿ëÀÚº°
  • ½ÃÀå ½Ã³ª¸®¿À(2022³â)

Á¦7Àå ¼¼°èÀÇ ÀÎÇ÷翣ÀÚ Áø´Ü ½ÃÀå Àü¸Á(2019-2032³â)

  • ½ÃÀå ±Ý¾× ½ÇÀû ºÐ¼®(2019-2024³â)
  • ÇöÀç¿Í ÇâÈÄ ½ÃÀå ±Ý¾× ¿¹Ãø(2025-2032³â)
    • Àü³âºñ ¼ºÀå µ¿Ç⠺м®
    • Àý´ëÀû ¼öÀÍ ±âȸ ºÐ¼®

Á¦8Àå ¼¼°èÀÇ ÀÎÇ÷翣ÀÚ Áø´Ü ½ÃÀå Àü¸Á : °Ë»çº°(2019-2032³â)

  • ¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
  • ½ÃÀå ±Ô¸ð ½ÇÀû ºÐ¼® : °Ë»çº°(2019-2024³â)
  • ÇöÀç¿Í ÇâÈÄ ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : °Ë»çº°(2025-2032³â)
    • ºÐÀÚÁø´Ü °Ë»ç
    • ±âÁ¸ Áø´Ü °Ë»ç
  • ½ÃÀå ¸Å·Â ºÐ¼® : °Ë»çº°

Á¦9Àå ÀÎÇ÷翣ÀÚ Áø´Ü ½ÃÀå Àü¸Á : ÀÎÇ÷翣ÀÚ À¯Çüº°(2019-2032³â)

  • ¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
  • ½ÃÀå ±Ô¸ð ½ÇÀû ºÐ¼® : ÀÎÇ÷翣ÀÚ À¯Çüº°(2019-2024³â)
  • ÇöÀç¿Í ÇâÈÄ ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ÀÎÇ÷翣ÀÚ À¯Çüº°(2025-2032³â)
    • AÇü ÀÎÇ÷翣ÀÚ
    • BÇü ÀÎÇ÷翣ÀÚ
    • CÇü ÀÎÇ÷翣ÀÚ
  • ½ÃÀå ¸Å·Â ºÐ¼® : ÀÎÇ÷翣ÀÚ À¯Çüº°

Á¦10Àå ÀÎÇ÷翣ÀÚ Áø´Ü ½ÃÀå Àü¸Á : ÃÖÁ¾»ç¿ëÀÚº°(2019-2032³â)

  • ¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
  • ½ÃÀå ±Ô¸ð ½ÇÀû ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°(2019-2024³â)
  • ÇöÀç¿Í ÇâÈÄ ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°(2025-2032³â)
    • º´¿ø
    • Áø´Ü °Ë»ç½Ç
    • ¿¬±¸¡¤Çмú±â°ü
    • ÀÓ»ó½ÃÇè¼öʱâ°ü(CRO)
  • ½ÃÀå ¸Å·Â ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

Á¦11Àå ÀÎÇ÷翣ÀÚ Áø´Ü ½ÃÀå Àü¸Á : Áö¿ªº°(2019-2032³â)

  • ¼Ò°³
  • ½ÃÀå ±Ô¸ð ½ÇÀû ºÐ¼® : Áö¿ªº°(2019-2024³â)
  • ÇöÀç¿Í ÇâÈÄ ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Áö¿ªº°(2025-2032³â)
    • ºÏ¹Ì
    • ¶óƾ¾Æ¸Þ¸®Ä«
    • À¯·´
    • ³²¾Æ½Ã¾Æ
    • µ¿¾Æ½Ã¾Æ
    • ¿À¼¼¾Æ´Ï¾Æ
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ½ÃÀå ¸Å·Â ºÐ¼® : Áö¿ªº°

Á¦12Àå ºÏ¹ÌÀÇ ÀÎÇ÷翣ÀÚ Áø´Ü ½ÃÀå Àü¸Á(2019-2032³â)

Á¦13Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ ÀÎÇ÷翣ÀÚ Áø´Ü ½ÃÀå Àü¸Á(2019-2032³â)

Á¦14Àå À¯·´ÀÇ ÀÎÇ÷翣ÀÚ Áø´Ü ½ÃÀå Àü¸Á(2019-2032³â)

Á¦15Àå ³²¾Æ½Ã¾ÆÀÇ ÀÎÇ÷翣ÀÚ Áø´Ü ½ÃÀå Àü¸Á(2019-2032³â)

Á¦16Àå µ¿¾Æ½Ã¾ÆÀÇ ÀÎÇ÷翣ÀÚ Áø´Ü ½ÃÀå Àü¸Á(2019-2032³â)

Á¦17Àå ¿À¼¼¾Æ´Ï¾ÆÀÇ ÀÎÇ÷翣ÀÚ Áø´Ü ½ÃÀå Àü¸Á(2019-2032³â)

Á¦18Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀÎÇ÷翣ÀÚ Áø´Ü ½ÃÀå Àü¸Á(2019-2032³â)

Á¦19Àå ½ÃÀå ±¸Á¶ ºÐ¼®

  • ½ÃÀå ºÐ¼® : ±â¾÷ Tierº°
  • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁß
  • ½ÃÀå ÀÔÁö ºÐ¼®

Á¦20Àå °æÀï ºÐ¼®

  • °æÀï ´ë½Ãº¸µå
  • °æÀï »ó¼¼
    • Abbott Laboratories
    • Endress+Hauser(Analytik Jena AG)
    • Becton, Dickinson and Company
    • Biocartis
    • bioMerieux Inc
    • Danaher Corporation(Cepheid)
    • F. Hoffmann-La Roche Ltd
    • GenMark Diagnostics, Inc.
    • Luminex Corporation
    • Meridian Bioscience, Inc
    • Quidel Corporation
    • Thermo Fisher Scientific Inc.
    • Hologic

Á¦21Àå »ç¿ëµÇ´Â °¡Á¤°ú µÎ¹®ÀÚ¾î

Á¦22Àå Á¶»ç ¹æ¹ý

ksm 25.04.01

Persistence Market Research has recently released a comprehensive report on the global Influenza Diagnostics Market, providing an in-depth analysis of key market dynamics, including driving factors, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, enabling stakeholders to make well-informed decisions.

Key Insights:

  • Influenza Diagnostics Market Size (2025E): USD 1,803.30 Mn
  • Projected Market Value (2032F): USD 2,711.50 Mn
  • Global Market Growth Rate (CAGR 2025 to 2032): 6.00%

Influenza Diagnostics Market - Report Scope:

The Influenza Diagnostics Market focuses on the development and adoption of diagnostic tools used to detect and identify influenza viruses, including influenza A, B, and C. The market is driven by the rising prevalence of seasonal and pandemic influenza, increasing demand for rapid and accurate diagnostic tests, and technological advancements in molecular and serological testing. The growing need for early and precise detection to curb disease outbreaks, along with increased investment in healthcare infrastructure, is further fueling market expansion.

Market Growth Drivers:

The global Influenza Diagnostics Market is experiencing significant growth due to multiple factors, including the increasing burden of influenza infections worldwide, rising awareness of early disease detection, and advancements in diagnostic technologies. Governments and healthcare organizations are emphasizing influenza surveillance and preparedness, further driving the adoption of influenza diagnostic tests. Additionally, the demand for point-of-care testing and the expansion of molecular diagnostic methods are propelling market growth.

Market Restraints:

Despite strong growth prospects, the market faces challenges such as high costs associated with molecular diagnostics and limited access to advanced healthcare facilities in certain regions. The accuracy of rapid diagnostic tests (RIDTs) remains a concern, as false-negative results can impact timely treatment. Regulatory hurdles and stringent approval processes for diagnostic kits may also slow market expansion.

Market Opportunities:

The Influenza Diagnostics Market presents substantial growth opportunities, including the development of innovative, high-sensitivity testing solutions and the integration of artificial intelligence (AI) in diagnostic platforms. Expansion into emerging markets and investments in point-of-care testing solutions can drive market penetration. Additionally, strategic collaborations between diagnostic manufacturers and healthcare providers will enhance product accessibility and affordability, further boosting market demand.

Key Questions Answered in the Report:

  • What are the major factors driving global growth in the Influenza Diagnostics Market?
  • How are molecular diagnostic advancements shaping the future of influenza testing?
  • Which diagnostic tests are witnessing the highest adoption rates?
  • Who are the key players in the Influenza Diagnostics Market, and what strategies are they implementing?
  • What are the emerging trends and market projections for influenza diagnostics?

Competitive Intelligence and Business Strategy:

Leading companies in the Influenza Diagnostics Market, such as Abbott Laboratories, Becton, Dickinson and Company, and Thermo Fisher Scientific Inc., are focusing on technological innovations, product launches, and strategic partnerships to strengthen their market presence. Companies are investing in molecular diagnostics, point-of-care testing, and AI-driven diagnostic solutions to enhance influenza detection accuracy and speed. Collaborations with research institutions and healthcare organizations help expand their market footprint and improve accessibility to advanced diagnostic solutions.

Key Companies Profiled:

  • Abbott Laboratories
  • Endress+Hauser (Analytik Jena AG)
  • Becton, Dickinson and Company
  • Biocartis
  • bioMerieux Inc.
  • Danaher Corporation (Cepheid)
  • F. Hoffmann-La Roche Ltd
  • GenMark Diagnostics, Inc.
  • Luminex Corporation
  • Meridian Bioscience, Inc.
  • Quidel Corporation
  • Thermo Fisher Scientific Inc.
  • Hologic

Influenza Diagnostics Industry Research by Category:

By Test Type:

  • Molecular Diagnostic Test
  • Traditional Diagnostic Test
  • H1N1 Influenza A Virus Identification Kits
  • Immunoassay Kits
  • Immunofluorescence Antibody Assay

By Type of Flu:

  • Type A Flu
  • Type B Flu
  • Type C Flu

By End User:

  • Hospitals
  • Diagnostic Laboratories
  • Research & Academic Institutes
  • Contract Research Organizations (CROs)

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Success Factors

  • 4.1. Product Adoption / Usage Analysis
  • 4.2. Product USPs / Features
  • 4.3. Strategic and Promotional Strategies
  • 4.4. Key Regulations
  • 4.5. Disease Epidemiology
  • 4.6. PESTLE Analysis
  • 4.7. Porter's Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Market Outlook
    • 5.1.3. Global Infectious Disease Diagnostics Market Overview
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Top Influenza Diagnostics Companies & their Historical Growth
    • 5.2.2. Application Innovation in Influenza Diagnostics
    • 5.2.3. Product Adoption Rate
    • 5.2.4. Regulatory Impositions
    • 5.2.5. Growing R&D Investments
    • 5.2.6. Novel Diagnostic Product Development Activities
    • 5.2.7. Awareness Campaigns for Influenza Diagnostics
  • 5.3. Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Test
    • 6.1.2. By Type of Flu
    • 6.1.3. By End User
  • 6.2. 2022 Market Scenario

7. Global Influenza Diagnostics Market Outlook, 2019-2032

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2024
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2025-2032
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Influenza Diagnostics Market Outlook, 2019-2032, By Test

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis By Test, 2019-2024
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Test, 2025-2032
    • 8.3.1. Molecular Diagnostics Tests
      • 8.3.1.1. RT-PCR
      • 8.3.1.2. LAMP
      • 8.3.1.3. NASABA
    • 8.3.2. Traditional Diagnostics Tests
      • 8.3.2.1. Rapid Influenza Detection Kits
      • 8.3.2.2. Serological Assays
      • 8.3.2.3. Direct Fluorescent Antibody
      • 8.3.2.4. Viral Culture
      • 8.3.2.5. H1N1 Influenza A Virus Identification Kits
      • 8.3.2.6. Immunoassay Kits
      • 8.3.2.7. Immunofluorescence Antibody Assay
  • 8.4. Market Attractiveness Analysis By Test

9. Global Influenza Diagnostics Market Outlook, 2019-2032, By Type of Flu

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis By Type of Flu, 2019-2024
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Type of Flu, 2025-2032
    • 9.3.1. Type A Flu
    • 9.3.2. Type B Flu
    • 9.3.3. Type C Flu
  • 9.4. Market Attractiveness Analysis By Type of Flu

10. Global Influenza Diagnostics Market Outlook, 2019-2032, by End User

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) Analysis By End User, 2019-2024
  • 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2025-2032
    • 10.3.1. Hospitals
    • 10.3.2. Diagnostic Laboratories
    • 10.3.3. Research & Academic Institutes
    • 10.3.4. Contract Research Organizations (CRO)
  • 10.4. Market Attractiveness Analysis By End User

11. Global Influenza Diagnostics Market Outlook, 2019-2032, by Region

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2024
  • 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2025-2032
    • 11.3.1. North America
    • 11.3.2. Latin America
    • 11.3.3. Europe
    • 11.3.4. South Asia
    • 11.3.5. East Asia
    • 11.3.6. Oceania
    • 11.3.7. Middle East and Africa (MEA)
  • 11.4. Market Attractiveness Analysis By Region

12. North America Influenza Diagnostics Market Outlook, 2019 - 2032

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2024
  • 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 12.3.1. By Country
      • 12.3.1.1. U.S.
      • 12.3.1.2. Canada
    • 12.3.2. By Test
    • 12.3.3. By Type of Flu
    • 12.3.4. By End User
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Test
    • 12.4.3. By Type of Flu
    • 12.4.4. By End User
  • 12.5. Country Level Analysis & Forecast
    • 12.5.1. U.S. Influenza Diagnostics Market Analysis
      • 12.5.1.1. Introduction
      • 12.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 12.5.1.2.1. By Test
        • 12.5.1.2.2. By Type of Flu
        • 12.5.1.2.3. By End User
    • 12.5.2. Canada Influenza Diagnostics Market Analysis
      • 12.5.2.1. Introduction
      • 12.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 12.5.2.2.1. By Test
        • 12.5.2.2.2. By Type of Flu
        • 12.5.2.2.3. By End User
  • 12.6. Market Trends
  • 12.7. Key Market Participants - Intensity Mapping
  • 12.8. Drivers and Restraints - Impact Analysis
  • 12.9. Country Level Analysis & Forecast

13. Latin America Influenza Diagnostics Market Outlook, 2019 - 2032

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2024
  • 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 13.3.1. By Country
      • 13.3.1.1. Brazil
      • 13.3.1.2. Mexico
      • 13.3.1.3. Argentina
      • 13.3.1.4. Rest of Latin America
    • 13.3.2. By Test
    • 13.3.3. By Type of Flu
    • 13.3.4. By End User
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Test
    • 13.4.3. By Type of Flu
    • 13.4.4. By End User
  • 13.5. Country Level Analysis & Forecast
    • 13.5.1. Brazil Influenza Diagnostics Market Analysis
      • 13.5.1.1. Introduction
      • 13.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.1.2.1. By Test
        • 13.5.1.2.2. By Type of Flu
        • 13.5.1.2.3. By End User
    • 13.5.2. Mexico Influenza Diagnostics Market Analysis
      • 13.5.2.1. Introduction
      • 13.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.2.2.1. By Test
        • 13.5.2.2.2. By Type of Flu
        • 13.5.2.2.3. By End User
    • 13.5.3. Argentina Influenza Diagnostics Market Analysis
      • 13.5.3.1. Introduction
      • 13.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.3.2.1. By Test
        • 13.5.3.2.2. By Type of Flu
        • 13.5.3.2.3. By End User
  • 13.6. Market Trends
  • 13.7. Key Market Participants - Intensity Mapping
  • 13.8. Drivers and Restraints - Impact Analysis
  • 13.9. Country Level Analysis & Forecast

14. Europe Influenza Diagnostics Market Outlook, 2019-2032

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2024
  • 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 14.3.1. By Country
      • 14.3.1.1. Germany
      • 14.3.1.2. France
      • 14.3.1.3. Italy
      • 14.3.1.4. U.K.
      • 14.3.1.5. Spain
      • 14.3.1.6. Russia
      • 14.3.1.7. BENELUX
      • 14.3.1.8. Rest of Europe
    • 14.3.2. By Test
    • 14.3.3. By Type of Flu
    • 14.3.4. By End User
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Test
    • 14.4.3. By Type of Flu
    • 14.4.4. By End User
  • 14.5. Country Level Analysis & Forecast
    • 14.5.1. Germany Influenza Diagnostics Market Analysis
      • 14.5.1.1. Introduction
      • 14.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.1.2.1. By Test
        • 14.5.1.2.2. By Type of Flu
        • 14.5.1.2.3. By End User
    • 14.5.2. France Influenza Diagnostics Market Analysis
      • 14.5.2.1. Introduction
      • 14.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.2.2.1. By Test
        • 14.5.2.2.2. By Type of Flu
        • 14.5.2.2.3. By End User
    • 14.5.3. Italy Influenza Diagnostics Market Analysis
      • 14.5.3.1. Introduction
      • 14.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.3.2.1. By Test
        • 14.5.3.2.2. By Type of Flu
        • 14.5.3.2.3. By End User
    • 14.5.4. U.K. Influenza Diagnostics Market Analysis
      • 14.5.4.1. Introduction
      • 14.5.4.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.4.2.1. By Test
        • 14.5.4.2.2. By Type of Flu
        • 14.5.4.2.3. By End User
    • 14.5.5. Spain Influenza Diagnostics Market Analysis
      • 14.5.5.1. Introduction
      • 14.5.5.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.5.2.1. By Test
        • 14.5.5.2.2. By Type of Flu
        • 14.5.5.2.3. By End User
    • 14.5.6. Russia Influenza Diagnostics Market Analysis
      • 14.5.6.1. Introduction
      • 14.5.6.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.6.2.1. By Test
        • 14.5.6.2.2. By Type of Flu
        • 14.5.6.2.3. By End User
    • 14.5.7. BENELUX Influenza Diagnostics Market Analysis
      • 14.5.7.1. Introduction
      • 14.5.7.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.7.2.1. By Test
        • 14.5.7.2.2. By Type of Flu
        • 14.5.7.2.3. By End User
  • 14.6. Market Trends
  • 14.7. Key Market Participants - Intensity Mapping
  • 14.8. Drivers and Restraints - Impact Analysis
  • 14.9. Country Level Analysis & Forecast

15. South Asia Influenza Diagnostics Market Outlook, 2019 - 2032

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2024
  • 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 15.3.1. By Country
      • 15.3.1.1. India
      • 15.3.1.2. Thailand
      • 15.3.1.3. Indonesia
      • 15.3.1.4. Malaysia
      • 15.3.1.5. Rest of South Asia
    • 15.3.2. By Test
    • 15.3.3. By Type of Flu
    • 15.3.4. By End User
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Test
    • 15.4.3. By Type of Flu
    • 15.4.4. By End User
  • 15.5. Country Level Analysis & Forecast
    • 15.5.1. India Influenza Diagnostics Market Analysis
      • 15.5.1.1. Introduction
      • 15.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.1.2.1. By Test
        • 15.5.1.2.2. By Type of Flu
        • 15.5.1.2.3. By End User
    • 15.5.2. Thailand Influenza Diagnostics Market Analysis
      • 15.5.2.1. Introduction
      • 15.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.2.2.1. By Test
        • 15.5.2.2.2. By Type of Flu
        • 15.5.2.2.3. By End User
    • 15.5.3. Indonesia Influenza Diagnostics Market Analysis
      • 15.5.3.1. Introduction
      • 15.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.3.2.1. By Test
        • 15.5.3.2.2. By Type of Flu
        • 15.5.3.2.3. By End User
    • 15.5.4. Malaysia Influenza Diagnostics Market Analysis
      • 15.5.4.1. Introduction
      • 15.5.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.4.2.1. By Test
        • 15.5.4.2.2. By Type of Flu
        • 15.5.4.2.3. By End User
  • 15.6. Market Trends
  • 15.7. Key Market Participants - Intensity Mapping
  • 15.8. Drivers and Restraints - Impact Analysis
  • 15.9. Country Level Analysis & Forecast

16. East Asia Influenza Diagnostics Market Outlook, 2019 - 2032

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2024
  • 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 16.3.1. By Country
      • 16.3.1.1. China
      • 16.3.1.2. Japan
      • 16.3.1.3. South Korea
    • 16.3.2. By Test
    • 16.3.3. By Type of Flu
    • 16.3.4. By End User
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Test
    • 16.4.3. By Type of Flu
    • 16.4.4. By End User
  • 16.5. Country Level Analysis & Forecast
    • 16.5.1. China Influenza Diagnostics Market Analysis
      • 16.5.1.1. Introduction
      • 16.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.5.1.2.1. By Test
        • 16.5.1.2.2. By Type of Flu
        • 16.5.1.2.3. By End User
    • 16.5.2. Japan Influenza Diagnostics Market Analysis
      • 16.5.2.1. Introduction
      • 16.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.5.2.2.1. By Test
        • 16.5.2.2.2. By Type of Flu
        • 16.5.2.2.3. By End User
    • 16.5.3. South Korea Influenza Diagnostics Market Analysis
      • 16.5.3.1. Introduction
      • 16.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.5.3.2.1. By Test
        • 16.5.3.2.2. By Type of Flu
        • 16.5.3.2.3. By End User
  • 16.6. Market Trends
  • 16.7. Key Market Participants - Intensity Mapping
  • 16.8. Drivers and Restraints - Impact Analysis
  • 16.9. Country Level Analysis & Forecast

17. Oceania Influenza Diagnostics Market Outlook, 2019-2032

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2024
  • 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 17.3.1. By Country
      • 17.3.1.1. Australia
      • 17.3.1.2. New Zealand
    • 17.3.2. By Test
    • 17.3.3. By Type of Flu
    • 17.3.4. By End User
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Test
    • 17.4.3. By Type of Flu
    • 17.4.4. By End User
  • 17.5. Country Level Analysis & Forecast
    • 17.5.1. Australia Influenza Diagnostics Market Analysis
      • 17.5.1.1. Introduction
      • 17.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.5.1.2.1. By Test
        • 17.5.1.2.2. By Type of Flu
        • 17.5.1.2.3. By End User
    • 17.5.2. New Zealand Influenza Diagnostics Market Analysis
      • 17.5.2.1. Introduction
      • 17.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.5.2.2.1. By Test
        • 17.5.2.2.2. By Type of Flu
        • 17.5.2.2.3. By End User
  • 17.6. Market Trends
  • 17.7. Key Market Participants - Intensity Mapping
  • 17.8. Drivers and Restraints - Impact Analysis
  • 17.9. Country Level Analysis & Forecast

18. Middle East and Africa Influenza Diagnostics Market Outlook, 2019 - 2032

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2024
  • 18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 18.3.1. By Country
      • 18.3.1.1. GCC Countries
      • 18.3.1.2. Turkey
      • 18.3.1.3. South Africa
      • 18.3.1.4. North Africa
      • 18.3.1.5. Rest of Middle East and Africa
    • 18.3.2. By Test
    • 18.3.3. By Type of Flu
    • 18.3.4. By End User
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Test
    • 18.4.3. By Type of Flu
    • 18.4.4. By End User
  • 18.5. Country Level Analysis & Forecast
    • 18.5.1. GCC Countries Influenza Diagnostics Market Analysis
      • 18.5.1.1. Introduction
      • 18.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 18.5.1.2.1. By Test
        • 18.5.1.2.2. By Type of Flu
        • 18.5.1.2.3. By End User
    • 18.5.2. Turkey Influenza Diagnostics Market Analysis
      • 18.5.2.1. Introduction
      • 18.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 18.5.2.2.1. By Test
        • 18.5.2.2.2. By Type of Flu
        • 18.5.2.2.3. By End User
    • 18.5.3. South Africa Influenza Diagnostics Market Analysis
      • 18.5.3.1. Introduction
      • 18.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 18.5.3.2.1. By Test
        • 18.5.3.2.2. By Type of Flu
        • 18.5.3.2.3. By End User
    • 18.5.4. North Africa Influenza Diagnostics Market Analysis
      • 18.5.4.1. Introduction
      • 18.5.4.2. Market Analysis and Forecast by Market Taxonomy
        • 18.5.4.2.1. By Test
        • 18.5.4.2.2. By Type of Flu
        • 18.5.4.2.3. By End User
  • 18.6. Drivers and Restraints - Impact Analysis
  • 18.7. Market Trends
  • 18.8. Key Market Participants - Intensity Mapping
  • 18.9. Country Level Analysis & Forecast

19. Market Structure Analysis

  • 19.1. Market Analysis by Tier of Companies
  • 19.2. Market Share Analysis of Top Players
  • 19.3. Market Concentration
  • 19.4. Market Presence Analysis

20. Competition Analysis

  • 20.1. Competition Dashboard
  • 20.2. Competition Deep Dive
    • 20.2.1. Abbott Laboratories
      • 20.2.1.1. Overview
      • 20.2.1.2. Product Portfolio
      • 20.2.1.3. Key Financials
      • 20.2.1.4. Sales Footprint
      • 20.2.1.5. Strategy Overview
        • 20.2.1.5.1. Marketing Strategy
        • 20.2.1.5.2. Product Strategy
        • 20.2.1.5.3. Channel Strategy
    • 20.2.2. Endress+Hauser (Analytik Jena AG)
      • 20.2.2.1. Overview
      • 20.2.2.2. Product Portfolio
      • 20.2.2.3. Key Financials
      • 20.2.2.4. Sales Footprint
      • 20.2.2.5. Strategy Overview
        • 20.2.2.5.1. Marketing Strategy
        • 20.2.2.5.2. Product Strategy
        • 20.2.2.5.3. Channel Strategy
    • 20.2.3. Becton, Dickinson and Company
      • 20.2.3.1. Overview
      • 20.2.3.2. Product Portfolio
      • 20.2.3.3. Key Financials
      • 20.2.3.4. Sales Footprint
      • 20.2.3.5. Strategy Overview
        • 20.2.3.5.1. Marketing Strategy
        • 20.2.3.5.2. Product Strategy
        • 20.2.3.5.3. Channel Strategy
    • 20.2.4. Biocartis
      • 20.2.4.1. Overview
      • 20.2.4.2. Product Portfolio
      • 20.2.4.3. Key Financials
      • 20.2.4.4. Sales Footprint
      • 20.2.4.5. Strategy Overview
        • 20.2.4.5.1. Marketing Strategy
        • 20.2.4.5.2. Product Strategy
        • 20.2.4.5.3. Channel Strategy
    • 20.2.5. bioMerieux Inc
      • 20.2.5.1. Overview
      • 20.2.5.2. Product Portfolio
      • 20.2.5.3. Key Financials
      • 20.2.5.4. Sales Footprint
      • 20.2.5.5. Strategy Overview
        • 20.2.5.5.1. Marketing Strategy
        • 20.2.5.5.2. Product Strategy
        • 20.2.5.5.3. Channel Strategy
    • 20.2.6. Danaher Corporation (Cepheid)
      • 20.2.6.1. Overview
      • 20.2.6.2. Product Portfolio
      • 20.2.6.3. Key Financials
      • 20.2.6.4. Sales Footprint
      • 20.2.6.5. Strategy Overview
        • 20.2.6.5.1. Marketing Strategy
        • 20.2.6.5.2. Product Strategy
        • 20.2.6.5.3. Channel Strategy
    • 20.2.7. F. Hoffmann-La Roche Ltd
      • 20.2.7.1. Overview
      • 20.2.7.2. Product Portfolio
      • 20.2.7.3. Key Financials
      • 20.2.7.4. Sales Footprint
      • 20.2.7.5. Strategy Overview
        • 20.2.7.5.1. Marketing Strategy
        • 20.2.7.5.2. Product Strategy
        • 20.2.7.5.3. Channel Strategy
    • 20.2.8. GenMark Diagnostics, Inc.
      • 20.2.8.1. Overview
      • 20.2.8.2. Product Portfolio
      • 20.2.8.3. Key Financials
      • 20.2.8.4. Sales Footprint
      • 20.2.8.5. Strategy Overview
        • 20.2.8.5.1. Marketing Strategy
        • 20.2.8.5.2. Product Strategy
        • 20.2.8.5.3. Channel Strategy
    • 20.2.9. Luminex Corporation
      • 20.2.9.1. Overview
      • 20.2.9.2. Product Portfolio
      • 20.2.9.3. Key Financials
      • 20.2.9.4. Sales Footprint
      • 20.2.9.5. Strategy Overview
        • 20.2.9.5.1. Marketing Strategy
        • 20.2.9.5.2. Product Strategy
        • 20.2.9.5.3. Channel Strategy
    • 20.2.10. Meridian Bioscience, Inc
      • 20.2.10.1. Overview
      • 20.2.10.2. Product Portfolio
      • 20.2.10.3. Key Financials
      • 20.2.10.4. Sales Footprint
      • 20.2.10.5. Strategy Overview
        • 20.2.10.5.1. Marketing Strategy
        • 20.2.10.5.2. Product Strategy
        • 20.2.10.5.3. Channel Strategy
    • 20.2.11. Quidel Corporation
      • 20.2.11.1. Overview
      • 20.2.11.2. Product Portfolio
      • 20.2.11.3. Key Financials
      • 20.2.11.4. Sales Footprint
      • 20.2.11.5. Strategy Overview
        • 20.2.11.5.1. Marketing Strategy
        • 20.2.11.5.2. Product Strategy
        • 20.2.11.5.3. Channel Strategy
    • 20.2.12. Thermo Fisher Scientific Inc.
      • 20.2.12.1. Overview
      • 20.2.12.2. Product Portfolio
      • 20.2.12.3. Key Financials
      • 20.2.12.4. Sales Footprint
      • 20.2.12.5. Strategy Overview
        • 20.2.12.5.1. Marketing Strategy
        • 20.2.12.5.2. Product Strategy
        • 20.2.12.5.3. Channel Strategy
    • 20.2.13. Hologic
      • 20.2.13.1. Overview
      • 20.2.13.2. Product Portfolio
      • 20.2.13.3. Key Financials
      • 20.2.13.4. Sales Footprint
      • 20.2.13.5. Strategy Overview
        • 20.2.13.5.1. Marketing Strategy
        • 20.2.13.5.2. Product Strategy
        • 20.2.13.5.3. Channel Strategy

21. Assumptions and Acronyms Used

22. Research Methodology

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦